On 4 November, T3D Therapeutics, a clinical stage drug development company developing new drugs for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) and Huntington’s disease, announced it has secured the funding to initiate its Phase II PIONEER study of T3D-959 for the treatment of AD. This investigational drug is designed to improve glucose and lipid metabolism dysfunctions present in AD.
The funding includes USD 15 million from an investor and USD 9 million received from a grant by the National Institute on Aging, part of the National Institutes of Health. The company is now fully funded to begin its Phase II PIONEER study. It is a double-blind, placebo-controlled and parallel-group trial evaluating the safety and efficacy of different doses of T3D-959 in people with mild to moderate AD. Starting in early 2020, the trial is expected to enroll up to 250 participants.
